RVNC REVANCE THERAPEUTICS INC revenue, earnings and financials
For the quarter ended September 30, 2024, REVANCE THERAPEUTICS INC reported revenue of $59.9M (up 10.7% from a year earlier), net income of −$38.1M and diluted EPS of −$0.37; over the last four quarters revenue was $257M and net income −$184M; for the fiscal year ended December 2023 revenue was $234M, up 76.5% on the year before.
RVNC annual revenue and earnings
- Fiscal year ended Dec 2023: revenue $234M, gross profit n/a, operating income −$317M, net income −$324M (margin -138.4%), EPS −$3.83
- Fiscal year ended Dec 2022: revenue $133M, gross profit n/a, operating income −$342M, net income −$356M (margin -268.9%), EPS −$4.90
- Fiscal year ended Dec 2021: revenue $77.8M, gross profit n/a, operating income −$275M, net income −$281M (margin -361.6%), EPS −$4.17
RVNC quarterly revenue and earnings
- Quarter ended Sep 30, 2024: revenue $59.9M (up 10.7% year over year), net income −$38.1M, EPS −$0.37
- Quarter ended Jun 30, 2024: revenue $65.4M (up 20.2% year over year), net income −$37.5M, EPS −$0.36
- Quarter ended Mar 31, 2024: revenue $51.9M (up 13.5% year over year), net income −$53.2M, EPS −$0.58
- Quarter ended Dec 31, 2023 (from the annual report): revenue $79.7M (up 59.7% year over year), net income −$55.7M, EPS −$0.66
- Quarter ended Sep 30, 2023: revenue $54.1M (up 86.5% year over year), net income −$141M, EPS −$1.63
- Quarter ended Jun 30, 2023: revenue $54.4M (up 91.8% year over year), net income −$67.3M, EPS −$0.80
- Quarter ended Mar 31, 2023: revenue $45.8M (up 81.2% year over year), net income −$59.8M, EPS −$0.74
- Quarter ended Dec 31, 2022 (from the annual report): revenue $49.9M (up 92.4% year over year), net income −$146M, EPS −$1.91
- Quarter ended Sep 30, 2022: revenue $29.0M (up 46.9% year over year), net income −$84.7M, EPS −$1.17
- Quarter ended Jun 30, 2022: revenue $28.4M (up 50.9% year over year), net income −$61.4M, EPS −$0.88
- Quarter ended Mar 31, 2022: revenue $25.3M (up 89.9% year over year), net income −$64.3M, EPS −$0.94
- Quarter ended Dec 31, 2021 (from the annual report): revenue $26.0M, net income −$63.1M, EPS −$0.92
- Quarter ended Sep 30, 2021: revenue $19.7M, net income −$74.4M, EPS −$1.10
- Quarter ended Jun 30, 2021: revenue $18.8M, net income −$72.2M, EPS −$1.07
- Quarter ended Mar 31, 2021: revenue $13.3M, net income −$71.6M, EPS −$1.08
RVNC cash flow, buybacks and dividends
- Fiscal year ended Dec 2023: operating cash flow −$217M, share buybacks n/a
- Fiscal year ended Dec 2022: operating cash flow −$194M, share buybacks n/a
- Fiscal year ended Dec 2021: operating cash flow −$222M, share buybacks n/a
RVNC balance sheet
- Sep 30, 2024: cash $58.6M, total assets $462M, total liabilities $625M, shareholders' equity −$163M, long-term debt $421M
- Jun 30, 2024: cash $81.5M, total assets $495M, total liabilities $625M, shareholders' equity −$130M, long-term debt $423M
- Mar 31, 2024: cash $133M, total assets $508M, total liabilities $607M, shareholders' equity −$98.7M, long-term debt $425M
- Dec 31, 2023: cash $137M, total assets $478M, total liabilities $630M, shareholders' equity −$152M, long-term debt $427M
- Sep 30, 2023: cash $179M, total assets $532M, total liabilities $639M, shareholders' equity −$106M, long-term debt $427M
- Jun 30, 2023: cash $141M, total assets $598M, total liabilities $571M, shareholders' equity $26.8M
- Mar 31, 2023: cash $137M, total assets $548M, total liabilities $574M, shareholders' equity −$26.7M
- Dec 31, 2022: cash $109M, total assets $582M, total liabilities $569M, shareholders' equity $12.6M, long-term debt $379M
What is RVNC's revenue?
REVANCE THERAPEUTICS INC reported $257M of revenue over its last four quarters, through September 30, 2024.
Is RVNC profitable?
No. REVANCE THERAPEUTICS INC lost $184M over the last four quarters.
What is RVNC's EPS?
Diluted earnings per share over the last four quarters were −$1.97; −$0.37 in the latest quarter.